|
|
|
|
||
Re: Quiet period (deal) theory...Also, just to close the loop and complete my thoughts on this, you said: "And no one is going to commit $500 million upfront to Sangamo for a 50/50 program, I think. Since Sangamo got $150 million upfront on the last program, perhaps similar for any 50/50 program, whether Tregs, Tau, Sangamo-brain-AAv, or CNS. $150 million upfront for a 50/50 seems a steep but not if the as yet unpublished IVPRP can lock down success in lysosomal storage disorders." I wholeheartedly disagree. SGMO was behind the competition in the CAR-T space. GILD bought the CAR-T expertise from KITE for ~$12B and then had to tack on 150M and ~3B in milestones to get SGMO to add their allogeneic secret sauce. In this case, SGMO owns both the CAR-TReg (think KITE) and allogenic secret sauce. Effectively they are the one stop shop for allogeneic CAR-TReg and they are arguably the leaders in the space. All they really need is an infusion of capital and personnel. They will be able to come up with the capital themselves if need be on the heels of IVPRP. I strongly believe if $500M got a 50/50 partnership done that there would be multiple interested parties knocking at their door. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
116795 | Re: Quiet period (deal) theory... | rynotheknife | 8 | 12/19/2018 6:29:30 AM |